Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
In full responders to clopidogrel scheduled to undergo PCI for NSTEACS, the use of abciximab
bolus only plus 600 mg clopidogrel loading dose will result in a non-inferior inhibition of
platelet aggregation after 4 hours as measured by LTA (20micromol ADP) when compared with
abciximab plus infusion and 300 mg clopidogrel loading dose.
Phase:
Phase 4
Details
Lead Sponsor:
Università degli Studi di Ferrara
Treatments:
Abciximab Antibodies, Monoclonal Clopidogrel Immunoglobulin Fab Fragments Ticlopidine